15th March 2016 Content supplied by: Eurofins Scientific Group
Eurofins Expands into Asia Pacific Biopharma Contract Testing Market
Eurofins Scientific has entered into the biopharmaceutical products testing market in the Asia Pacific region with the acquisition of ams Laboratories Pty Ltd. the leading independent analytical and cGMP Quality Control (QC) services provider for biopharmaceutical products and medical devices in Australia.
Founded 20 years ago, ams Laboratories has grown rapidly to become one of the top three, and the largest pure-play biopharmaceutical products testing provider in the domestic market, serving the biopharma and medical devices industries. The company employs 45 staff across its 2 sites in Sydney and Brisbane. In the past decade, it has grown well above Eurofins' annual organic growth objective, and generated revenues in excess of EUR 5m for the fiscal year 2015, the majority of which is from biopharmaceutical products testing. The company is also active in medical device testing, as well as in probiotics and nutraceutical testing.
The acquisition of ams Laboratories provides Eurofins with a strong entry platform to deploy its market-leading biopharmaceutical testing capabilities to support the pharmaceutical and biotechnology industries in the Asia Pacific region. Furthermore, it allows Eurofins to expand into medical device testing in the region, which is entirely complementary to its existing biopharma capabilities. The company therefore presents an excellent geographical and operational fit for the Group.
ams Laboratories further expands the Eurofins global biopharma service offering, and will enable the Group to further leverage its existing client relationships in Europe and North America, and accelerate its expanding client reach in Asia Pacific, which still represents a vast potential growth market for drug development.
In return, ams will benefit from access to the complete range of Eurofins' portfolio of services as the global reference in biopharmaceutical testing, which will enable it to expand its service offering and its footprint in the biopharmaceutical and medical device testing markets, as well as in the nutraceutical testing market in the region.
Comment from Dr. Gilles Martin, Eurofins CEO: "The acquisition of ams Laboratories provides Eurofins a platform to deploy its renowned capabilities in biopharmaceutical products testing in the Asia Pacific region, and reinforces the Group's global leadership in the biopharmaceutical products testing market. We look forward to expanding and strengthening ams Laboratories' footprint by providing them access to the full range of Eurofins' capabilities."
Date Published: 15th March 2016
Source article link: View
First FDA-Cleared Test for Carbapenem
uBiome Appoints Microbiome Self-Experimenter as